Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Transplant ; 33(12): e13749, 2019 12.
Article in English | MEDLINE | ID: mdl-31691354

ABSTRACT

BACKGROUND: The vigilance of tacrolimus (TAC) trough levels is an essential part of renal transplant follow up. Reduced TAC trough levels and high variability are related to adverse outcomes. The aim of this study was to evaluate the impact of brand changes on tacrolimus (TAC) subtherapeutic (SubT) trough levels, acute rejection (AR), and kidney function. METHODS: This is a prospective, observational cohort study of renal transplant recipients, between January 2016 and October 2018. Tacrolimus trough levels and brand used by the patient were both registered at every consult. Tacrolimus values ≤3.5 ng/mL were considered SubT. RESULTS: 445 patients were included. The median number of TAC brand changes was 2 (IQR, 1-4). Patients were grouped according to the number of brand changes: Group 1 = 0 (n = 107), Group 2 = 1-4 (n = 236), and Group 3 = ≥5 (n = 102). Patients with the greatest number of brand changes had a greater proportion and number of SubT TAC trough levels (Group 1 = 36.4%, average 0.53; Group 2 = 39.8%, average 0.65, Group 3 = 59.8%, average 1.17, P < .001) and AR (Group 1 = 0.9%, Group 2 = 11%, Group 3 = 14.7%, P < .001). On multivariate analysis, SubT levels and the number of brand changes were related to AR. CONCLUSIONS: In Mexico, changes in TAC brand are associated with an elevated frequency of SubT levels. Brand changes and SubT levels are independently associated with acute rejection. The supply policies on TAC brands in Mexico require revision to avoid changing brands as much as possible.


Subject(s)
Graft Rejection/etiology , Kidney Failure, Chronic/surgery , Kidney Transplantation/adverse effects , Postoperative Complications/etiology , Tacrolimus/adverse effects , Tacrolimus/blood , Transplant Recipients/statistics & numerical data , Adult , Female , Follow-Up Studies , Glomerular Filtration Rate , Graft Rejection/blood , Graft Rejection/pathology , Graft Survival , Humans , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/blood , Kidney Function Tests , Male , Postoperative Complications/blood , Postoperative Complications/pathology , Prognosis , Prospective Studies , Risk Factors
2.
Curr Neuropharmacol ; 17(10): 947-960, 2019.
Article in English | MEDLINE | ID: mdl-31146657

ABSTRACT

Endocannabinoids are ancient biomolecules involved in several cellular (e.g., metabolism) and physiological (e.g., eating behaviour) functions. Indeed, eating behaviour alterations in marijuana users have led to investigate the orexigenic/anorexigenic effects of cannabinoids in animal/ human models. This increasing body of research suggests that the endocannabinoid system plays an important role in feeding control. Accordingly, within the endocannabinoid system, cannabinoid receptors, enzymes and genes represent potential therapeutic targets for dealing with multiple metabolic and behavioural dysfunctions (e.g., obesity, anorexia, etc.). Paradoxically, our understanding on the endocannabinoid system as a cellular mediator is yet limited. For example: (i) only two cannabinoid receptors have been classified, but they are not enough to explain the pharmacological profile of several experimental effects induced by cannabinoids; and (ii) several orphan G protein-coupled receptors (GPCRs) interact with cannabinoids and we do not know how to classify them (e.g., GPR18, GPR55 and GPR119; amongst others). On this basis, the present review attempts to summarize the lines of evidence supporting the potential role of GPR18, GPR55 and GPR119 in metabolism and feeding control that may explain some of the divergent effects and puzzling data related to cannabinoid research. Moreover, their therapeutic potential in feeding behaviour alterations will be considered.


Subject(s)
Endocannabinoids/metabolism , Endocannabinoids/pharmacology , Receptors, Cannabinoid/metabolism , Receptors, G-Protein-Coupled/metabolism , Animals , Cannabinoids , Endocannabinoids/chemistry , Endocannabinoids/physiology , Humans , Receptors, Cannabinoid/physiology , Receptors, G-Protein-Coupled/physiology
3.
Transplant Proc ; 48(2): 669-72, 2016 Mar.
Article in English | MEDLINE | ID: mdl-27110026

ABSTRACT

BACKGROUND: Diabetes is complex disease, which involves primary metabolic changes followed by immunological and vascular pathophysiological adjustments. However, it is mostly characterized by an unbalanced decreased number of the ß-cells unable to maintain the metabolic requirements and failure to further regenerate newly functional pancreatic islets. The objective of this study was to analyze the properties of the endothelial cells to facilitate the islet cells engraftment after islet transplantation. METHODS: We devised a co-cultured engineer system to coat isolated islets with vascular endothelial cells. To assess the cell integration of cell-engineered islets, we stained them for endothelial marker CD31 and nuclei counterstained with DAPI dye. We comparatively performed islet transplantations into streptozotocin-induced diabetic mice and recovered the islet grafts for morphometric analyses on days 3, 7, 10, and 30. Blood glucose levels were measured continuously after islet transplantation to monitor the functional engraftment and capacity to achieve metabolic control. RESULTS: Cell-engineered islets showed a well-defined rounded shape after co-culture when compared with native isolated islets. Furthermore, the number of CD31-positive cells layered on the islet surface showed a direct proportion with engraftment capacities and less TUNEL-positive cells on days 3 and 7 after transplantation. CONCLUSIONS: We observed that vascular endothelial cells could be functional integrated into isolated islets. We also found that islets that are coated with vascular endothelial cells increased their capacity to engraft. These findings indicate that islets coated with endothelial cells have a greater capacity of engraftment and thus establish a definitely vascular network to support the metabolic requirements.


Subject(s)
Endothelial Cells/cytology , Islets of Langerhans Transplantation/methods , Animals , Coculture Techniques/methods , Diabetes Mellitus, Experimental/therapy , Endothelial Cells/transplantation , Female , Insulin-Secreting Cells/cytology , Insulin-Secreting Cells/transplantation , Islets of Langerhans/cytology , Mice, Inbred BALB C , Random Allocation
SELECTION OF CITATIONS
SEARCH DETAIL
...